A cytochrome P450-derived epoxygenated metabolite of anandamide is a potent cannabinoid receptor 2-selective agonist.
paper
Cited
Public
Unavailable
- Authors
- Snider, Natasha T; Nast, James A; Tesmer, Laura A; Hollenberg, Paul F
- Year
- 2009
- Journal
- Molecular pharmacology
- PMID
- 19171674
- DOI
- 10.1124/mol.108.053439
- PMCID
- PMC2684935
Oxidation of the endocannabinoid anandamide by cytochrome P450 (P450) enzymes has the potential to affect signaling pathways within the endocannabinoid system and pharmacological responses to novel drug candidates targeting this system. We previously reported that the human cytochromes P450 2D6, 3A4, and 4F2 are high-affinity, high-turnover anandamide oxygenases in vitro, forming the novel metabolites hydroxyeicosatetraenoic acid ethanolamides and epoxyeicosatrienoic acid ethanolamides. The objective of this study was to investigate the possible biological significance of these metabolic pathways. We report that the 5,6-epoxide of anandamide, 5,6-epoxyeicosatrienoic acid ethanolamide (5,6-EET-EA), is a potent and selective cannabinoid receptor 2 (CB2) agonist. The K(i) values for the binding of 5,6-EET-EA to membranes from Chinese hamster ovary (CHO) cells expressing either recombinant human CB1 or CB2 receptor were 11.4 microM and 8.9 nM, respectively. In addition, 5,6-EET-EA inhibited the forskolin-stimulated accumulation of cAMP in CHO cells stably expressing the CB2 receptor (IC(50) = 9.8 +/- 1.3 nM). Within the central nervous system, the CB2 receptor is expressed on activated microglia and is a potential therapeutic target for neuroinflammation. BV-2 microglial cells stimulated with low doses of interferon-gamma exhibited an increased capacity for converting anandamide to 5,6-EET-EA, which correlated with increased protein expression of microglial P450 4F and 3A isoforms. Finally, we demonstrate that 5,6-EET-EA is more stable than anandamide in mouse brain homogenates and is primarily metabolized by epoxide hydrolase. Combined, our results suggest that epoxidation of anandamide by P450s to form 5,6-EET-EA represents an endocannabinoid bioactivation pathway in the context of immune cell function.
No figures extracted from this document.
No chunks β full text not yet ingested.
No entities extracted from this document yet.
No uploaded files.
Not in any collection.
No citations found.
In this knowledge base
External
| Title | Authors | Journal | Year | Link |
|---|---|---|---|---|
| Molecular mechanisms of cytochrome P450-derived epoxy-fatty acids neuroprotection. | Navarro-Mabarak C et al. | β | 2025 | β |
| The endocannabinoidomes: Pharmacological redundancy and promiscuity, and multi-kingdom variety of sources and molecular targets. | Iannotti FA et al. | β | 2025 | β |
| The Hunt for the Putative Epoxyeicosatrienoic Acid Receptor. | Arnold WR et al. | β | 2025 | β |
| Exploring the versatile roles of the endocannabinoid system and phytocannabinoids in modulating bacterial infections. | Barker H et al. | β | 2024 | β |
| Anandamide and other N-acylethanolamines: A class of signaling lipids with therapeutic opportunities. | Mock ED et al. | β | 2023 | β |
| Assay of Endocannabinoid Oxidation by Cytochrome P450. | Snider NT et al. | β | 2023 | β |
| Fatty acid binding proteins are novel modulators of synaptic epoxyeicosatrienoic acid signaling in the brain. | Glaser ST et al. | β | 2023 | β |
| Goods and Bads of the Endocannabinoid System as a Therapeutic Target: Lessons Learned after 30 Years. | Maccarrone M et al. | β | 2023 | β |
| Biosynthesis and metabolism of endocannabinoids and their congeners from the monoacylglycerol and N-acyl-ethanolamine families. | Simard M et al. | β | 2022 | β |
| Detoxification Cytochrome P450s (CYPs) in Families 1-3 Produce Functional Oxylipins from Polyunsaturated Fatty Acids. | Eccles JA et al. | β | 2022 | β |
| Human CYP2B6 produces oxylipins from polyunsaturated fatty acids and reduces diet-induced obesity. | Heintz MM et al. | β | 2022 | β |
| Intracellular Molecular Targets and Signaling Pathways Involved in Antioxidative and Neuroprotective Effects of Cannabinoids in Neurodegenerative Conditions. | Tadijan A et al. | β | 2022 | β |
| Synergistic action between a synthetic cannabinoid compound and tramadol in neuropathic pain rats. | QuiΓ±onez-Bastidas GN et al. | β | 2022 | β |
| Anti-inflammatory dopamine- and serotonin-based endocannabinoid epoxides reciprocally regulate cannabinoid receptors and the TRPV1 channel. | Arnold WR et al. | β | 2021 | β |
| Cannabidiol and Neurodevelopmental Disorders in Children. | Kwan Cheung KA et al. | β | 2021 | β |
| Cannabinoids pharmacological effects are beyond the palliative effects: CB2 cannabinoid receptor agonist induced cytotoxicity and apoptosis in human colorectal cancer cells (HT-29). | Alenabi A et al. | β | 2021 | β |
| Cannabinoid Therapeutics in Chronic Neuropathic Pain: From Animal Research to Human Treatment. | Campos RMP et al. | β | 2021 | β |
| Disentangling the Molecular Mechanisms of the Antidepressant Activity of Omega-3 Polyunsaturated Fatty Acid: A Comprehensive Review of the Literature. | Kalkman HO et al. | β | 2021 | β |
| Endocannabinoid signaling pathways: beyond CB1R and CB2R. | Biringer RG | β | 2021 | β |
| Further exploration of the structure-activity relationship of dual soluble epoxide hydrolase/fatty acid amide hydrolase inhibitors. | Wilt S et al. | β | 2021 | β |
| The rise and fall of anandamide: processes that control synthesis, degradation, and storage. | Biringer RG | β | 2021 | β |
| A large-scale genome-wide association study meta-analysis of cannabis use disorder. | Johnson EC et al. | β | 2020 | β |
| CYP2J2 Molecular Recognition: A New Axis for Therapeutic Design. | Das A et al. | β | 2020 | β |
| Cytochrome P450 derived epoxidized fatty acids as a therapeutic tool against neuroinflammatory diseases. | Atone J et al. | β | 2020 | β |
| Gender differences in diet-induced steatotic disease in Cyp2b-null mice. | Heintz MM et al. | β | 2020 | β |
| Mitochondrial-related effects of pentabromophenol, tetrabromobisphenol A, and triphenyl phosphate on murine BV-2 microglia cells. | Bowen C et al. | β | 2020 | β |
| Soluble Epoxide Hydrolase Regulation of Lipid Mediators Limits Pain. | Wagner KM et al. | β | 2020 | β |
| Targeting CYP2J2 to Enhance the Anti-Glioma Efficacy of Cannabinoid Receptor 2 Stimulation by Inhibiting the Pro-Angiogenesis Function of M2 Microglia. | Lei X et al. | β | 2020 | β |
| Oxidized Lipids in Persistent Pain States. | Osthues T et al. | β | 2019 | β |
| Role of epoxy-fatty acids and epoxide hydrolases in the pathology of neuro-inflammation. | Kodani SD et al. | β | 2019 | β |
| The Interplay between the Endocannabinoid System, Epilepsy and Cannabinoids. | Cheung KAK et al. | β | 2019 | β |
| The role of n-3 PUFA-derived fatty acid derivatives and their oxygenated metabolites in the modulation of inflammation. | de Bus I et al. | β | 2019 | β |
| Cross-talk of cannabinoid and endocannabinoid metabolism is mediated via human cardiac CYP2J2. | Arnold WR et al. | β | 2018 | β |
| Design and Potency of Dual Soluble Epoxide Hydrolase/Fatty Acid Amide Hydrolase Inhibitors. | Kodani SD et al. | β | 2018 | β |
| Endocannabinoid Virodhamine Is an Endogenous Inhibitor of Human Cardiovascular CYP2J2 Epoxygenase. | Carnevale LN et al. | β | 2018 | β |
| High fat diet induced obesity is mitigated in Cyp3a-null female mice. | Kumar R et al. | β | 2018 | β |
| LC-MS/MS Analysis of the Epoxides and Diols Derived from the Endocannabinoid Arachidonoyl Ethanolamide. | Rand AA et al. | β | 2018 | β |
| Neuroprotection in Oxidative Stress-Related Neurodegenerative Diseases: Role of Endocannabinoid System Modulation. | Paloczi J et al. | β | 2018 | β |
| Therapeutic Effect of the Substrate-Selective COX-2 Inhibitor IMMA in the Animal Model of Chronic Constriction Injury. | Jones M et al. | β | 2018 | β |
| Anti-inflammatory Ο-3 endocannabinoid epoxides. | McDougle DR et al. | β | 2017 | β |
| Endocannabinoid Turnover. | Fowler CJ et al. | β | 2017 | β |
| Arachidonoyl-ethanolamide activates endoplasmic reticulum stress-apoptosis in tumorigenic keratinocytes: Role of cyclooxygenase-2 and novel J-series prostamides. | Soliman E et al. | β | 2016 | β |
| Emerging roles for brain drug-metabolizing cytochrome P450 enzymes in neuropsychiatric conditions and responses to drugs. | Toselli F et al. | β | 2016 | β |
| Metabolism of Anandamide by Human Cytochrome P450 2J2 in the Reconstituted System and Human Intestinal Microsomes. | Walker VJ et al. | β | 2016 | β |
| The modulatory effect of anandamide on nitroglycerin-induced sensitization in the trigeminal system of the rat. | Nagy-GrΓ³cz G et al. | β | 2016 | β |
| Endocannabinoid metabolism by cytochrome P450 monooxygenases. | Zelasko S et al. | β | 2015 | β |
| Endocannabinoids and their oxygenation by cyclo-oxygenases, lipoxygenases and other oxygenases. | Urquhart P et al. | β | 2015 | β |
| Endocannabinoids modulate human blood-brain barrier permeability in vitro. | Hind WH et al. | β | 2015 | β |
| Peripheral FAAH and soluble epoxide hydrolase inhibitors are synergistically antinociceptive. | Sasso O et al. | β | 2015 | β |
| Regulation of inflammation by cannabinoids, the endocannabinoids 2-arachidonoyl-glycerol and arachidonoyl-ethanolamide, and their metabolites. | Turcotte C et al. | β | 2015 | β |
| COX-2-derived endocannabinoid metabolites as novel inflammatory mediators. | Alhouayek M et al. | β | 2014 | β |
| Endocannabinoids anandamide and 2-arachidonoylglycerol are substrates for human CYP2J2 epoxygenase. | McDougle DR et al. | β | 2014 | β |
| Endocannabinoids, related compounds and their metabolic routes. | Fezza F et al. | β | 2014 | β |
| Endocannabinoid system and pain: an introduction. | Burston JJ et al. | β | 2014 | β |
| Ketoconazole inhibits the cellular uptake of anandamide via inhibition of FAAH at pharmacologically relevant concentrations. | BjΓΆrklund E et al. | β | 2014 | β |
| Stabilized epoxygenated fatty acids regulate inflammation, pain, angiogenesis and cancer. | Zhang G et al. | β | 2014 | β |
| Cytochrome P450 4F2 polymorphism in patients with liver cirrhosis. | Vavilin VA et al. | β | 2013 | β |
| Dynamic changes to the endocannabinoid system in models of chronic pain. | Rani Sagar D et al. | β | 2012 | β |
| Increase of 20-HETE synthase after brain ischemia in rats revealed by PET study with 11C-labeled 20-HETE synthase-specific inhibitor. | Kawasaki T et al. | β | 2012 | β |
| New insights on endocannabinoid transmission in psychomotor disorders. | Giuffrida A et al. | β | 2012 | β |
| Anandamide oxidation by wild-type and polymorphically expressed CYP2B6 and CYP2D6. | Sridar C et al. | β | 2011 | β |
| Endocannabinoid oxygenation by cyclooxygenases, lipoxygenases, and cytochromes P450: cross-talk between the eicosanoid and endocannabinoid signaling pathways. | Rouzer CA et al. | β | 2011 | β |
| Lipoxygenase-mediated oxidation of polyunsaturated N-acylethanolamines in Arabidopsis. | Kilaru A et al. | β | 2011 | β |
| Soluble epoxide hydrolase inhibition, epoxygenated fatty acids and nociception. | Wagner K et al. | β | 2011 | β |
| Effects of a commonly occurring genetic polymorphism of human CYP3A4 (I118V) on the metabolism of anandamide. | Pratt-Hyatt M et al. | β | 2010 | β |
| Effects of COX-2 inhibition on spinal nociception: the role of endocannabinoids. | Staniaszek LE et al. | β | 2010 | β |
| Epoxyeicosanoid signaling in CNS function and disease. | Iliff JJ et al. | β | 2010 | β |
| In vivo pharmacology of endocannabinoids and their metabolic inhibitors: therapeutic implications in Parkinson's disease and abuse liability. | Giuffrida A et al. | β | 2010 | β |
| Modulation of the endocannabinoid system: neuroprotection or neurotoxicity? | Fowler CJ et al. | β | 2010 | β |
| Oxidation of the endogenous cannabinoid arachidonoyl ethanolamide by the cytochrome P450 monooxygenases: physiological and pharmacological implications. | Snider NT et al. | β | 2010 | β |
| Dynamic regulation of the endocannabinoid system: implications for analgesia. | Sagar DR et al. | β | 2009 | β |